A recent IASLC consensus statement encourages definitive RT to the primary site after induction therapy particularly in what subset of metastatic NSCLC?
Does there seem to be a difference on control between clear cell and non-clear cell RCC treated with SABR?
Does the use of a CTV margin reduce local recurrence after SBRT for nonspine bone metastases?
Answers
EGFR mutated. Growing data supports definitive RT to the primary tumor in select patients with stage IV NSCLC, particularly those with targetable mutations. Several ongoing phase 3 trials (NIRVANA-Lung, PRIME-Lung, TOURIST, MARS) should clarify whether non-mutated patients derive similar benefit from definitive treatment of the primary.
No. In this retrospective study of over 200 patients, there were no differences in control or survival based on histology.
No, at least not small to modest CTV margins such as 5mm. Most recurrences were marginal or out of field, and only 28% would have been encompassed by a 2cm margin. | QuadShot News
Does there seem to be a difference on control between clear cell and non-clear cell RCC treated with SABR?
Does the use of a CTV margin reduce local recurrence after SBRT for nonspine bone metastases?
Answers
EGFR mutated. Growing data supports definitive RT to the primary tumor in select patients with stage IV NSCLC, particularly those with targetable mutations. Several ongoing phase 3 trials (NIRVANA-Lung, PRIME-Lung, TOURIST, MARS) should clarify whether non-mutated patients derive similar benefit from definitive treatment of the primary.
No. In this retrospective study of over 200 patients, there were no differences in control or survival based on histology.
No, at least not small to modest CTV margins such as 5mm. Most recurrences were marginal or out of field, and only 28% would have been encompassed by a 2cm margin. | QuadShot News